Mechanical Aortic Valve Thromboembolism During Pregnancy on Low Molecular Weight Heparin Authors: Rebecca Philpott, Cassandra Voong, Khalil Jalkh, Stephanie Dunlap, Gyanendra Sharma Published: 2023 ABSTRACT AbstractA 31-year-old pregnant woman with a mechanical aortic valve developed a thrombus on her mechanical aortic valve due to subtherapeutic low molecular weight heparin dosage. She received intravenous heparin followed by warfarin. low molecular weight heparin dosing in pregnancy should be individualized, considering weight, physiological changes, and adjusted based on levels.Key Words: aortic valve, anticoagulation, pregnancy, thrombus History of presentation A 31-year-old pregnant woman, gravida 3, para 2, at 26 weeks of gestation presented to the emergency department with severe right-sided abdominal pain and nausea. Onset of pain started a month prior, described initially as dull and localized with no significant associated symptoms. On the day of presentation, patient experienced acute worsening of her pain, now sharp in quality, localized to the right upper quadrant. Pain was associated with nausea. No exacerbating or relieving factors. No chest pain, no shortness of breath, no lower extremity edema, no fever, no chills, and no other remarkable were reported on review of systems. During the physical examination, a systolic ejection murmur was noted at the right upper sternal border, but there was no audible mechanical click. Abdominal exam showed tenderness at the right costo-vertebral angle; there was no rebound tenderness or guarding. The patient's vital signs remained hemodynamically stable. She had been receiving 80 mg of low molecular weight heparin (LMWH) injection twice a day, maintaining therapeutic peak levels throughout her pregnancy. Learning Objectives •To understand evaluating signs of valve thrombosis and treatment response during pregnancy. To understand evaluating signs of valve thrombosis and treatment response during pregnancy. •To recommend tailoring anticoagulation regimens and dosing individually, considering the specific circumstances of each case especially during pregnancy. To recommend tailoring anticoagulation regimens and dosing individually, considering the specific circumstances of each case especially during pregnancy. Past medical history At age 13 years, the patient underwent patch repair for a ventricular septal defect that had caused aortic insufficiency. In 2005, because of severe aortic insufficiency, she received a 23-mm mechanical St Jude Aortic valve replacement. Since then, the patient had been consistently taking warfarin; however, during pregnancy, she was transitioned to LMWH. During previous pregnancies, she received LMWH with dosing guided by peak and trough anti-Xa measurements. Her stable doses were 120 mg in the morning and 100 mg in the evening, with the patient weighing 65 kg. During the current pregnancy, the patient had received 1 mg/kg dosing and measured peak anti-Xa levels during the first 3 months only which were within therapeutic levels. Her most recent pregnancy revealed a fetus diagnosed with double outlet right ventricle, transposition of the great arteries, and ventricular septal defect that would require surgical correction at birth. Differential diagnosis The differential diagnoses on initial presentation included cholecystitis/cholelithiasis, nephrolithiasis, thromboembolic disease to abdominal viscera, appendicitis, ovarian cysts, and ovarian torsion. Investigations Ultrasound examination of the right upper quadrant, abdomen, and pregnancy revealed no presence of gallstones, ovarian cysts, ovarian torsion, pancreatic cysts, or abdominal fluid collection. However, the possibility of appendicitis could not be ruled out because it was not visualized, prompting a contrast-enhanced computed tomography scan of the abdomen, which revealed a right-sided renal infarction. Subsequently, a transthoracic echocardiogram (TTE) was performed and showed an increased mean aortic valve gradient of 42 mm Hg consistent with significant mechanical aortic valve obstruction (Figure 1). The patient's mean aortic valve gradient 3 months prior had been 23 mm Hg (Figure 2), whereas her pre-pregnancy TTE showed a mean aortic valve gradient of 11 mm Hg. The differential for increased mean gradient includes thrombus, pannus, and endocarditis. Mean AV Gradient on Initial TTE Continuous-wave Doppler measurements across left ventricular outflow tract–aorta performed during admission show new marked elevation in mean pressure gradient (42 mm Hg) indicative of valve stenosis/thrombosis. Mean Atrioventricular Gradient Measurement on Outpatient Transthoracic Echocardiogram Continuous-wave Doppler measurements across left ventricular outflow tract–aorta performed at previous clinic visits during current gestation showing mean pressure gradient of 21 mm Hg. Management The patient was admitted to the cardiovascular intensive care unit and initiated on a high-intensity intravenous heparin protocol (targeting anti-Xa level 0.5-0.7 IU/mL). A collaborative approach involving cardiology anesthesia, cardiology echocardiographer, and maternal-fetal medicine specialists led to a transesophageal echocardiogram (TEE) to assess the thrombus characteristics (Video 1). The TEE revealed an 8-mm thrombus on the ventricular side of the aortic valve (Figure 3). Consultation with a pediatric cardiothoracic surgeon was sought regarding the feasibility of thrombectomy, but due to the clot’s size being <10 mm, the surgery was deemed to have higher risk than benefit. Thrombolysis with tissue plasminogen activator (tPA) was considered but posed significant risks to the fetus, and early delivery was not a viable option due to the fetus' congenital heart defects. The patient had no symptoms of heart failure. She was hemodynamically stable; therefore, a cautious approach was adopted, continuing the high-intensity heparin infusion while monitoring aortic valve gradients through serial TTEs. Subsequent TTEs during the hospital stay showed a progressive decrease in mean gradients, declining from 31 mm Hg to 26 mm Hg and eventually to 19 mm Hg, suggesting a reduction in thrombus size (Figures 4, 5 and 6). As the fetus had completed organogenesis due to gestational age beyond the first trimester, a transition to warfarin was initiated with a target international normalized ratio (INR) of 3. Hematology was consulted to ensure a smooth transition process from heparin to warfarin. Once the INR reached 2.5, the heparin infusion was stopped and she was discharged home on warfarin, with close follow-up in the anticoagulation clinic. Transesophageal Echocardiogram View of Mechanical Aortic Valve Shown is an 8-mm thrombus found on the ventricular side of the aortic prosthesis. Mean Atrioventricular Gradient Measurement on Transthoracic Echocardiogram Continuous-wave Doppler measurements across left ventricular outflow tract–aorta performed day 3 after starting anticoagulation. Mean Atrioventricular Gradient Measurement on Transthoracic Echocardiogram (Day 7 of Admission) Continuous-wave Doppler measurements across left ventricular outflow tract–aorta performed day 7 after starting anticoagulation. Mean Atrioventricular Gradient Measurement on Transthoracic Echocardiogram (Day 11 of Admission) Continuous-wave Doppler measurements across left ventricular outflow tract–aorta performed day 11 after starting anticoagulation. She had a follow-up at another institution with an adult congenital heart specialist. She has remained well with stable aortic gradient and did not have any bleeding issues. Considering the patient’s history of requiring higher LMWH doses, a higher weight-based dose of 1.3 mg/kg (100 mg dose) was recommended if her INR dropped below goal. Discussion Pregnancy induces a prothrombotic state characterized by hormonal changes, increased circulating coagulation factors, and hemodynamic alterations.1 However, there are limited data available on anticoagulation strategies for managing prothrombotic conditions, such as mechanical aortic valves, during pregnancy. Existing studies often lack quality and do not provide comprehensive monitoring of anti-Xa or activated partial thromboplastin time levels. Three anticoagulation options are typically considered for pregnancy: full-term warfarin use, warfarin with transition to heparin or LMWH during weeks 6-12, or heparin/LMWH throughout the entire gestation.2 Each regimen has unique risks that necessitate thorough patient discussion. Warfarin, with an INR goal of 2.5 to 3.5 for mechanical valves, has a black box warning due to its teratogenic potential, resulting in nasal hypoplasia and epiphyseal stippling during weeks 6-12 of pregnancy.3 Moreover, warfarin crosses the placenta, increasing the risk of bleeding complications for both the baby and mother during delivery.4 Heparin and LMWH, on the other hand, pose a higher risk of thromboembolism as reported in various studies; however, peak and trough anti-Xa levels are often not included in these reports.5,6 Therapeutic peak levels according to the American College of Cardiology are 0.8 to 1.2 IU/mL at 4 to 6 hours after the dose. The accepted therapeutic trough level is arbitrarily placed at 0.6 IU/mL.6 Obstruction is a worrisome complication associated with mechanical valves necessitating regular monitoring for sudden changes in echocardiographic parameters. An abrupt increase in mean transvalvular gradient, specifically a rise of 15 mm Hg from baseline (for aortic valves) or exceeding 35 mm Hg, indicates potential valve obstruction resulting from either pannus or thrombus formation.7 To assess the nature of a thrombus and determine the appropriate course of action (surgical or medical intervention), TEE can be used. Thrombolytics are only considered if the mother is hemodynamically unstable.6 TTE is also valuable in assessing valve dysfunction through analysis of opening and closing spikes. The patient in this case exhibited an increased mean aortic valve gradient of 23 mm Hg (compared to a pre-pregnancy baseline of 11 mm Hg) on an echocardiogram conducted 2 months before presentation, which raised concerns; however, it did not meet the diagnostic criteria for obstruction. Despite therapeutic peak levels of LMWH (administered at lower doses of 1 mg/kg) during the early stages of this pregnancy, the patient still experienced thrombus formation. LMWH acts by binding to coagulation factors Xa and IIa in the plasma. During pregnancy, the plasma volume expands at a higher rate than red blood cell production, which may contribute to the increased risk of thromboembolism while on heparin or LMWH during pregnancy.1 Follow-up The patient was discharged on warfarin 5 mg daily with weekly follow-ups at the warfarin clinic until her delivery. The most recent TTE conducted before discharge had shown a consistent aortic mean gradient of 23 mm Hg, indicating stability (Figure 4). Conclusions Pregnant patients at high risk of coagulation complications necessitate diligent monitoring of LMWH dosing through the assessment of both peak and trough anti-Xa levels throughout the pregnancy as anticoagulation requirements can change as the pregnancy progresses. Routine echocardiograms are essential for pregnant patients with mechanical valves, carefully examining any changes compared to previous exams that may suggest thrombus formation. In cases where echocardiographic findings raise suspicion of thrombus, a higher degree of anticoagulation titration may be required. It is crucial to maintain a high index of suspicion for thromboembolism in pregnant patients at elevated risk of clotting, even if they are receiving anticoagulation therapy. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For a supplemental video, please see the online version of this paper. Appendix Video 1 Transesophageal echocardiography revealing a thrombus on the ventricular side of the mechanical aortic valve. References Associated Data Supplementary Materials Video 1 Transesophageal echocardiography revealing a thrombus on the ventricular side of the mechanical aortic valve.